Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET
- Dow leads Wall Street higher with 2% gain; cyclicals in vanguard
- Kohl's (KSS) Stock Tick Higher as Activist Investor Engine Capital Urges Board to Consider Sale
- Bitcoin (BTC) Price Remains Below $50,000 After Weekend Selloff, Analyst Expects a 'Hard Month'
- EV Rivian (RIVN) Shares Dip as Street Starts New Coverage With Mixed Ratings, Goldman Sachs and JPMorgan Initiate at Neutral Citing Lofty Valuation
- Dollar up against safe havens as risk sentiment improves on Omicron news
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
CAMBRIDGE,Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its third quarter 2021 financial results will be released on Thursday, November 4, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 7525705
Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 7525705
An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Fulcrum has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Please visit www.fulcrumtx.com.
Senior Vice President,
Corporate Communications and Investor Relations
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jack in the Box (JACK) to Acquire Del Taco (TACO) for $12.51 Per Share
- Gaming and Leisure Properties and The Cordish Companies Announce Strategic Relationship: GLPI to Acquire the Real Estate Assets of Three Cordish Live! Casino Properties for $1.81 Billion; Cordish to I
- Oral Arguments in CHD’s Case Challenging FCC’s OTARD Rule Allowing 5G Antennas on Homes set for December 7, 9:30 a.m. Eastern
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!